Last Updated: November 10, 2026
Quick Summary
Compounded GLP-1s are not disappearing overnight, but FDA rules are tightening fast after the semaglutide shortage ended on February 21, 2025. Compounding remains legal only for individualized prescriptions backed by a documented, patient-specific clinical reason.
- The FDA declared the national semaglutide shortage resolved on February 21, 2025.
- The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the bulks list on April 30, 2026.
- A 2026 JAMA Network analysis found 56% of 75 clinics offered GLP-1s combined with B vitamins.
- Safety analyses report compounded GLP-1s may be linked to abdominal pain, nausea, and diarrhea.
- Ask your prescriber which product you receive, where it was made, and why.
Table of Contents
- Why Compounded GLP-1s Are Under Scrutiny Now
- Timeline of FDA Policy Changes Since the Semaglutide Shortage Ended
- Who May Still Legally Receive a Compounded Medication
- Compounded Semaglutide Availability and Access Going Forward
- Compounded Semaglutide Safety: What the Research Shows
- FDA-Approved GLP-1 Alternatives and How They Compare
- Switching From Compounded Semaglutide: Questions to Ask Your Prescriber
- Frequently Asked Questions
Why Compounded GLP-1s Are Under Scrutiny Now
Compounded GLP-1s are not disappearing overnight, but the rules around them are tightening fast. Patients who rely on a compounded version of semaglutide or tirzepatide have a right to know what is changing and what it means for their care. Patients can work through these shifts with their prescriber to make informed decisions.
The FDA ended the national semaglutide shortage on February 21, 2025, which removed the legal basis for many mass-market compounded copies. FDA determination that the semaglutide shortage was resolved Since then, the agency has moved to restrict how compounders can market these products.
A 2026 JAMA Network analysis of 75 weight-loss clinics and medical spas found that 56% offered GLP-1 medications combined with B vitamins. JAMA Network analysis of clinic offerings of compounded GLP-1s That level of marketing is exactly what regulators are watching.
Safety is a second reason for scrutiny. Safety analyses have reported that compounded GLP-1 receptor agonists may be linked to abdominal pain, nausea, and diarrhea. PubMed safety analysis of compounded GLP-1 receptor agonists
Timeline of FDA Policy Changes Since the Semaglutide Shortage Ended
The FDA’s actions on compounded GLP-1s have come in a sequence of steps rather than a single rule change. Knowing the order, and what each step actually allows or blocks, is the fastest way to tell whether a product you are offered is still on solid legal ground.
- February 21, 2025: The FDA determined that the national semaglutide shortage was resolved. Once a drug is off the FDA’s shortage list, compounders can no longer rely on the shortage provisions that allowed them to make copies of it.
- Early 2026: The FDA issued guidance clarifying the conditions compounders must meet to qualify for exemptions under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Section 503A covers pharmacies compounding for specific patients on a prescription, while section 503B covers outsourcing facilities that may produce compounded drugs in larger batches.
- April 30, 2026: The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the bulks list. Ingredients on the bulks list are the raw substances that compounders use to make products, so removing these three drugs would make it far harder to mass-produce them under the compounding exemptions.
FDA clarifies policies for compounders as the national GLP-1 supply stabilizes
Two points help readers use this timeline. First, a proposed rule is not yet final, so the status of the bulks-list change should be rechecked before you rely on it. Second, these steps all push in the same direction: each one narrows what compounders can offer without a documented, patient-specific reason.
The FDA’s actions on compounded GLP-1s have come in a sequence of steps, and each one narrows what compounders can offer.
| Date | FDA action | Effect on compounders |
|---|---|---|
| February 21, 2025 | Semaglutide shortage declared resolved | Shortage provisions no longer apply |
| Early 2026 | Guidance on sections 503A and 503B exemptions | Stricter conditions for exemptions |
| April 30, 2026 | Proposed bulks-list exclusion | Semaglutide, tirzepatide, liraglutide targeted |
Who May Still Legally Receive a Compounded Medication
Compounding is not banned outright. A pharmacist may still prepare a medication for an individual patient when a licensed prescriber has a documented, patient-specific reason that an FDA-approved product will not serve that patient. The distinction that matters is between a compounded product made for one identified patient and a compounded product made in advance, in quantity, for general sale.
A simple way to sort your situation is to work through four questions in order:
- Is there a valid prescription for you specifically? A prescription written for you by a licensed prescriber, naming you as the patient, is the starting point. A product sold without one, or through a website that does not require a prescriber review, falls outside the individualized pathway.
- Is there a documented clinical reason for a compounded version? Examples of documented clinical reasons can include a need for a dose that no approved strength provides, or a need to remove an ingredient the patient cannot tolerate. A general preference for a lower price, by itself, is not the type of reason the individualized exemption is designed to cover.
- Is the pharmacy operating under the right federal pathway? Traditional pharmacies generally compound under section 503A, and outsourcing facilities generally operate under section 503B. Either pathway has conditions to be checked with the FDA. Ask whether the pharmacy is registered as an outsourcing facility if it describes itself that way, and whether it follows the FDA requirements that apply to its category.
- Does your state allow it? State pharmacy boards set their own rules on compounding and dispensing and can be stricter than federal law. The board in the state where the pharmacy is licensed is the authority to check.
A useful test for any offer: if the seller cannot tell you who your prescriber is, why a compounded version was chosen for you, and which federal pathway the product was made under, the offer does not match the individualized model described above. Watch out: an individualized prescription still has to be filled by a pharmacy that can show these three things, so a long-standing relationship with a clinic is not by itself evidence that every product it supplies is lawful.
Compounded Semaglutide Availability and Access Going Forward
Access may become narrower over time, and individualized prescriptions may remain available in limited cases.
Patients should plan for a few realities:
- Supply will depend on each pharmacy’s compliance with FDA rules.
- Individualized prescriptions may take longer to fill than mass-produced options.
- Costs can change as compounders adjust their operations.
Pricing depends on quantity, dates, and delivery. Contact MedShape Weight Loss Clinics or check our website for current pricing and a personal quote.
Compounded Semaglutide Safety: What the Research Shows
Safety data is still developing, and the research so far is not reassuring for every patient. Some reports suggest compounded GLP-1s may carry a higher risk of stomach side effects than FDA-approved versions. Those side effects include nausea, abdominal pain, and diarrhea.
Patients worried about tolerability should keep these points in mind:
- Ask your prescriber which product you are receiving and where it was made.
- Report side effects early rather than waiting for them to pass.
- Do not switch doses or products without medical guidance.
For a closer look at the evidence, see our guide on whether compounded semaglutide is safe in 2026.
FDA-Approved GLP-1 Alternatives and How They Compare
FDA-approved options include Ozempic, Wegovy, Mounjaro, and Zepbound. Each differs in its active ingredient, typical results, and dosing schedule.
- Ozempic and Wegovy contain semaglutide.
- Mounjaro and Zepbound contain tirzepatide.
Our guide to GLP-1 medications compared explains how these differ in mechanism, weight loss results, and dosing. You can also read our semaglutide versus tirzepatide comparison for a side-by-side view.
Switching From Compounded Semaglutide: Questions to Ask Your Prescriber
Switching medication is a medical decision. Bring these questions to your next appointment:

- Is my current product FDA-approved or compounded?
- Why do I need a change, and what other options fit my health history?
- How should I adjust my dose when I switch?
- What should I do if I miss a dose during the transition? Our guide on what to do if you miss a semaglutide dose covers the basics.
- How will we monitor my progress and side effects?
Your prescriber or pharmacist can answer these questions for your situation. Never make a switch on your own.
Compounded GLP-1s are under real pressure, and the rules will keep shifting. MedShape Weight Loss Clinics provides medically supervised weight loss care with board-certified physicians and nutrition specialists who build a plan around your health history. Talk with our team to learn what options fit your situation.
Frequently Asked Questions
Are compounded GLP-1s going away?
Not entirely. The FDA has moved to restrict mass-marketed compounded versions of these drugs. Compounding is still permitted on an individual, patient-specific basis under sections 503A and 503B when conditions are met. Patients should confirm with their prescriber and pharmacy whether their specific prescription remains lawful and available.
Can pharmacies still compound semaglutide?
Pharmacies may still compound semaglutide for an individual patient when a prescriber documents a clinical need, such as a documented need that an approved product cannot meet. Compounding a copy of an FDA-approved drug for routine use is what federal policy is restricting. Whether a given pharmacy can fill a given prescription depends on its licensure and state pharmacy board rules, so ask the pharmacy directly.
Are compounded GLP-1 medications FDA-approved?
No. Compounded drugs are prepared by pharmacies or outsourcing facilities and are not reviewed by the FDA for safety, effectiveness, or quality the way approved products are. The FDA does not approve compounded versions, though it does set standards for the bulk ingredients and oversees certain compounding facilities. This is why the approved medication and the compounded version can differ in strength, salt form, or added ingredients.
Is compounded semaglutide safe?
Safety data is limited. Some analyses have reported that compounded GLP-1 receptor agonists may be associated with a higher likelihood of adverse effects, including abdominal pain, nausea, and diarrhea, compared with FDA-approved versions. Product quality can also vary between compounders. Patients who have side effects or concerns should contact their prescriber promptly rather than adjusting doses on their own.